Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin

Figure 1

Effect of policosanol on serum levels of PCSK9. (a) In Protocol I, there was no significant difference in baseline serum levels of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) between the two treatment groups (both ). Treatment with atorvastatin 20 mg/day for 8 weeks significantly increased serum levels of PCSK9 (, shown as “∗”); however, when combined with policosanol 20 mg/day, it caused a trend toward increasing PCSK9, but it was not statistically significant (). (b) In Protocol II, there was no significant difference in baseline serum levels of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) between the two groups (both ). After treatment with policosanol 20 mg/day for 12 weeks, there was a trend toward decreasing PCSK9 in the policosanol group, although it did not reach statistical significance (, shown as “#”).

(a)

(b)